Revance published two peer-reviewed papers on its Daxxify wrinkle treatment in the Aesthetic Surgery Journal.

Revance Therapeutics announced the publication of two peer-reviewed papers about its Daxxify treatment in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society.

The publications highlight the nuances of glabellar line (GL) injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used.

The first publication, Impact of Glabellar Injection Technique with DaxibotulinumtoxinA for Injection on Brow Position, demonstrates the impact of subtle variations in glabellar line injection technique on eyebrow position.

The second paper, Integrative Assessment for Optimizing Aesthetic Outcomes When Treating Glabellar Lines with Botulinum Toxin Type A: An Appreciation of the Role Of The Frontalis, proposes a structured and comprehensive assessment algorithm focused on anatomical principles, allowing for an individualized treatment approach.

“These newly published manuscripts demonstrate Revance’s commitment to improving aesthetic patient outcomes,” said Conor Gallagher, vice president of medical affairs and scientific innovation at Revance. “We show for the first time, with supporting data, that small differences in glabellar line technique can impact both static and dynamic brow position outcomes. Although glabellar line treatment is often considered straightforward, secondary effects on eyebrow position can impact the broader aesthetic outcome, beyond the simple reduction of the frown lines.”

Daxxify (DaxibotulinumtoxinA-lanm) for injection is an FDA-approved long-lasting peptide-formulated neuromodulator product for use in adults for the temporary improvement of moderate to severe frown lines.

It can deliver results that last up to a year for patients with potentially only two treatments per year and has been shown to be effective, generally safe, and well tolerated, according to Revance. Daxxify is powered by a cell-penetrating peptide technology (Peptide Exchange Technology), Revance’s proprietary, synthetic, 35-amino-acid stabilizing excipient with a highly positive charge, and is free of human serum albumin or animal-based components.

Photo 139310522 © motortion |